Skip to main content

Advertisement

SpringerLink
Log in

A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

Dermatologic adverse events (dAEs) in cancer treatment are frequent with the use of targeted therapies. These dAEs have been shown to have significant impact on health-related quality of life (HRQoL). While standardized assessment tools have been developed for physicians to assess severity of dAEs, there is a discord between objective and subjective measures. The identification of patient-reported outcome (PRO) instruments useful in the context of targeted cancer therapies is therefore important in both the clinical and research settings for the overall evaluation of dAEs and their impact on HRQoL.

Methods

A comprehensive, systematic literature search of published articles was conducted by two independent reviewers in order to identify PRO instruments previously utilized in patient populations with dAEs from targeted cancer therapies. The identified PRO instruments were studied to determine which HRQoL issues relevant to dAEs were addressed, as well as the process of development and validation of these instruments.

Results

Thirteen articles identifying six PRO instruments met the inclusion criteria. Four instruments were general dermatology (Skindex-16©, Skindex-29©, Dermatology Life Quality Index (DLQI), and DIELH-24) and two were symptom-specific (functional assessment of cancer therapy-epidermal growth factor receptor inhibitor-18 (FACT-EGFRI-18) and hand-foot syndrome 14 (HFS-14)).

Conclusions

While there are several PRO instruments that have been tested in the context of targeted cancer therapy, additional work is needed to develop new instruments and to further validate the instruments identified in this study in patients receiving targeted therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Agha R, Kinahan K, Bennett CL, Lacouture ME (2007) Dermatologic challenges in cancer patients and survivors. Oncology (Williston Park, NY) 21(12):1462–1472, discussion 1473, 1476, 1481 passim

    Google Scholar 

  2. Joshi SS, Ortiz S, Witherspoon JN, Rademaker A, West DP, Anderson R, Rosenbaum SE, Lacouture ME (2010) Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer 116(16):3916–3923. doi:10.1002/cncr.25090

    Article  PubMed  Google Scholar 

  3. Chen A, Acharya A, Setser A (2013) Grading dermatologic adverse events in clinical trials using CTCAE v4.0. In: dermatologic principles and practice in oncology. Wiley, New Jersey, pp 47–59. doi:10.1002/9781118590638.ch5

    Book  Google Scholar 

  4. Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI, Schrag D (2006) Patient versus clinician symptom reporting using the national cancer institute common terminology criteria for adverse events: results of a questionnaire-based study. Lancet Oncol 7(11):903–909. doi:10.1016/s1470-2045(06)70910-x

    Article  PubMed  Google Scholar 

  5. Basch E (2012) Beyond the FDA PRO guidance: steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels. Value Health: J Int Soc Pharmacoeconomics Outcomes Res 15(3):401–403. doi:10.1016/j.jval.2012.03.1385

    Article  Google Scholar 

  6. Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M (2010) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol: Off J Am Soc Clin Oncol 28(8):1351–1357. doi:10.1200/jco.2008.21.7828

    Article  CAS  Google Scholar 

  7. Cano SJ, Klassen A, Pusic AL (2009) The science behind quality-of-life measurement: a primer for plastic surgeons. Plast Reconstr Surg 123(3):98e–106e. doi:10.1097/PRS.0b013e31819565c1

    Article  PubMed  Google Scholar 

  8. Aaronson N, Alonso J, Burnam A, Lohr KN, Patrick DL, Perrin E, Stein RE (2002) Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res Int J Qual Life Asp Treat Care Rehab 11(3):193–205

    Article  Google Scholar 

  9. Nardone B, Hensley JR, Kulik L, West DP, Mulcahy M, Rademaker A, Lacouture ME (2012) The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life. J Drugs Dermatol: JDD 11(11):e61–65

    PubMed  Google Scholar 

  10. Rosen AC, Case EC, Dusza SW, Balagula Y, Gordon J, West DP, Lacouture ME (2013) Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol 14(4):327–333. doi:10.1007/s40257-013-0021-0

    Article  PubMed  Google Scholar 

  11. Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, Novotny PJ, Schaefer PL, Johnson DB, Tschetter LK, Loprinzi CL (2008) Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the north central cancer treatment group (N03CB). Cancer 113(4):847–853. doi:10.1002/cncr.23621

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Andreis F, Rizzi A, Mosconi P, Braun C, Rota L, Meriggi F, Mazzocchi M, Zaniboni A (2010) Quality of life in colon cancer patients with skin side effects: preliminary results from a monocentric cross sectional study. Health Qual Life Outcomes 8:40. doi:10.1186/1477-7525-8-40

    Article  PubMed Central  PubMed  Google Scholar 

  13. Osio A, Mateus C, Soria JC, Massard C, Malka D, Boige V, Besse B, Robert C (2009) Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Br J Dermatol 161(3):515–521. doi:10.1111/j.1365-2133.2009.09214.x

    Article  CAS  PubMed  Google Scholar 

  14. Unger K, Niehammer U, Hahn A, Goerdt S, Schumann M, Thum S, Schepp W (2013) Treatment of metastatic colorectal cancer with cetuximab: influence on the quality of life. Z Gastroenterol 51(8):733–739. doi:10.1055/s-0033-1335064

    Article  CAS  PubMed  Google Scholar 

  15. Wagner LI, Berg SR, Gandhi M, Hlubocky FJ, Webster K, Aneja M, Cella D, Lacouture ME (2013) The development of a functional assessment of cancer therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18). Support Care Cancer: Off J Multinatl Assoc Support Care in Cancer 21(4):1033–1041. doi:10.1007/s00520-012-1623-4

    Article  Google Scholar 

  16. Boers-Doets CB, Gelderblom H, Lacouture ME, Epstein JB, Nortier JW, Kaptein AA (2013) Experiences with the FACT-EGFRI-18 instrument in EGFRI-associated mucocutaneous adverse events. Support Care Cancer: Off J Multinatl Assoc Support Care Cancer 21(7):1919–1926. doi:10.1007/s00520-013-1752-4

    Article  Google Scholar 

  17. Sibaud V, Dalenc F, Chevreau C, Roche H, Delord JP, Mourey L, Lacaze JL, Rahhali N, Taieb C (2011) HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. Oncologist 16(10):1469–1478. doi:10.1634/theoncologist. 2011-0033

    Article  PubMed Central  PubMed  Google Scholar 

  18. Taieb C, Sibaud V (2009) PCN82 HFS 14: a specific quality of life instrument for patients with hand-foot syndrome. Value Health 12(3):A52

    Article  Google Scholar 

  19. Teo YL, Chong XJ, Chue XP, Chau NM, Tan MH, Kanesvaran R, Wee HL, Ho HK, Chan A (2014) Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation. Cancer Chemother Pharmacol 73(2):381–388. doi:10.1007/s00280-013-2360-1

    Article  CAS  PubMed  Google Scholar 

  20. Chren MM (2012) The Skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin 30(2):231–236. doi:10.1016/j.det.2011.11.003, xiii

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Chren MM, Lasek RJ, Sahay AP, Sands LP (2001) Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg 5(2):105–110. doi:10.1007/s102270000010

    Article  CAS  PubMed  Google Scholar 

  22. Finlay AY, Khan GK (1994) Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol 19(3):210–216

    Article  CAS  PubMed  Google Scholar 

  23. Lewis V, Finlay AY (2004) 10 years experience of the Dermatology Life Quality Index (DLQI). The journal of investigative dermatology Symposium proceedings / the Society for Investigative Dermatology, Inc [and] European Society for Dermatological Research 9 (2):169–180. doi:10.1111/j.1087-0024.2004.09113.x

  24. Finlay AY, Basra MK, Piguet V, Salek MS (2012) Dermatology life quality index (DLQI): a paradigm shift to patient-centered outcomes. J Invest Dermatol 132(10):2464–2465. doi:10.1038/jid.2012.147

    Article  CAS  PubMed  Google Scholar 

  25. Schafer T, Staudt A, Ring J (2001) German instrument for the assessment of quality of life in skin diseases (DIELH). Internal consistency, reliability, convergent and discriminant validity and responsiveness. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 52(7):624–628

    Article  CAS  PubMed  Google Scholar 

  26. Chen AP, Setser A, Anadkat MJ, Cotliar J, Olsen EA, Garden BC, Lacouture ME (2012) Grading dermatologic adverse events of cancer treatments: the common terminology criteria for adverse events version 4.0. J Am Acad Dermatol 67(5):1025–1039. doi:10.1016/j.jaad.2012.02.010

    Article  PubMed  Google Scholar 

  27. Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME (2007) Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 72(3–4):152–159. doi:10.1159/000112795

    Article  CAS  PubMed  Google Scholar 

  28. Wagner LI, Lacouture ME (2007) Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist’s perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park, NY) 21(11):34–36

    Google Scholar 

  29. Velikova G, Booth L, Smith AB, Brown PM, Lynch P, Brown JM, Selby PJ (2004) Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol Off J Am Soc Clin Oncol 22(4):714–724. doi:10.1200/jco.2004.06.078

    Article  Google Scholar 

  30. Wagner LI, Cella D (2013) Psychosocial issues in oncology: clinical management of psychosocial distress, health-related quality of life, and special considerations in dermatologic oncology. In: dermatologic principles and practice in oncology. Wiley, Hoboken, pp 60–68. doi:10.1002/9781118590638.ch6

    Google Scholar 

Download references

Acknowledgments

None.

Conflict of interest

Dr. Roeland has a consultant role with Cellulitix.

Dr. Choi has received remuneration from Onyx Pharmaceuticals and has a consultant role with Biotest AG.

Dr. Bryce has a consultant role with AstraZeneca and Roche.

Dr. Gerber has a consultant role with Galderma International. He is also receiving research funding from Hoffman La Roche.

Dr. Lacouture has a consultant role with AstraZeneca, Roche, Bayer, Janssen, Exelixis, Advancell, BMS, Amgen and Genentech. He is also receiving research funding from Berg, Roche and BMS.

Sources of funding

There were no sources of funding used in this study. The authors have full control of the primary data, which is available to the journal at their request for review.

Author information

Authors and Affiliations

  1. Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore, Republic of Singapore

    Alexandre Chan & Yi Ling Teo

  2. University of South Florida Morsani College of Medicine, Tampa, FL, USA

    Michael C. Cameron

  3. Department of Dermatology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    Benjamin Garden, Katja Schindler & Mario E. Lacouture

  4. IMPAQTT, Wormer, The Netherlands

    Christine B. Boers-Doets

  5. Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands

    Christine B. Boers-Doets

  6. Department of Dermatology, Medical University of Vienna, Vienna, Austria

    Katja Schindler

  7. Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA

    Joel B. Epstein

  8. Yale University School of Medicine, New Haven, CT, USA

    Jennifer Choi

  9. School of Nursing & Health Studies, Northern Illinois University, DeKalb, IL, USA

    Laura Beamer

  10. Moores Cancer Center, University of California San Diego, La Jolla, CA, USA

    Eric Roeland

  11. Department of Radiation Oncology, AO. S. Croce e Carle Teaching Hospital, Cuneo, Italy

    Elvio G. Russi

  12. Centre de Haute Energie, Nice, France

    René-Jean Bensadoun

  13. Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia

    Raymond J. Chan

  14. National Cancer Centre Singapore, Singapore, Republic of Singapore

    Vivianne Shih

  15. National Cancer Institute, Naples, Italy

    Jane Bryce

  16. Department of Oral and Maxillofacial Surgery, Academic Medical Center Amsterdam and Department of Medical Dental Interaction Academic Centre of Dentistry, Amsterdam, The Netherlands

    Judith Raber-Durlacher

  17. Heinrich Heine University, Düsseldorf, Germany

    Peter Arne Gerber

  18. University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

    César O. Freytes

  19. The Medical Oncology Centre of Rosebank, Johannesburg, South Africa

    Bernardo Rapoport

  20. Dana-Farber Cancer Institute, Boston, MA, USA

    Nicole LeBoeuf

  21. Cancer University Institute of Toulouse Oncopole, Toulouse, France

    Vincent Sibaud

  22. Memorial Sloan-Kettering Cancer Center, Rockefeller Outpatient Pavilion, Suite 228, 160 E 53rd St, New York, NY, 10022, USA

    Mario E. Lacouture

Authors
  1. Alexandre Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael C. Cameron
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Benjamin Garden
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christine B. Boers-Doets
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Katja Schindler
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Joel B. Epstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jennifer Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Laura Beamer
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Eric Roeland
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Elvio G. Russi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. René-Jean Bensadoun
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yi Ling Teo
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Raymond J. Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Vivianne Shih
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Jane Bryce
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Judith Raber-Durlacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Peter Arne Gerber
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. César O. Freytes
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Bernardo Rapoport
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Nicole LeBoeuf
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Vincent Sibaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Mario E. Lacouture
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mario E. Lacouture.

Appendices

Appendix 1

Table 3 Search strategies and terms used
Full size table

Appendix 2. Skindex-29© [21]

figure a

Appendix 3. Skindex-16© [21]

figure b

Appendix 4. Dermatology Life Quality Index (DLQI) [22]

figure c

Appendix 5. Functional Assessment of Cancer Therapy-Epidermal Growth Factor Receptor Inhibitors-18 (FACT-EGFRI-18) [15]

figure d

Appendix 6. Hand-Foot Syndrome 14 [HFS 14] [17]

figure e

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chan, A., Cameron, M.C., Garden, B. et al. A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies. Support Care Cancer 23, 2231–2244 (2015). https://doi.org/10.1007/s00520-014-2564-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-014-2564-x

Keywords

Search

Navigation